HCPCS code J1747 — Inj, spesolimab-sbzo, 1 mg.
Status: Active.
Effective Apr 1, 2023.
Source: CMS HCPCS Level II.
J1747
ActiveInj, spesolimab-sbzo, 1 mg
Injection, spesolimab-sbzo, 1 mg
Category:
Drugs
Section:
J-codes: Drugs Administered Other Than Oral Method
Effective:
Apr 1, 2023
Code type:
alphanumeric
OPPS Status:
K
— Non-pass-through drugs and biologicals
OPPS APC:
9115
MUE — Medically Unlikely Edits
Maximum units of J1747 Medicare will pay for one beneficiary on one date of service. Claims exceeding the MUE are denied or returned for review.
| Service Type | Max Units / Day |
|---|---|
| Outpatient Hospital | 900 |
| Practitioner Services | 900 |
Source: CMS Medicare NCCI Medically Unlikely Edits
NDC Crosswalk
National Drug Codes (NDCs) mapped to this HCPCS code.
| NDC | Drug Name |
|---|---|
| 00597-0035-10 | Spevigo |
| 00597-0620-20 | Spevigo |
| 00597-7705-41 | Spevigo Pfs |
| 00597-7705-72 | Spevigo Pfs |
Change History
Quarterly changes published by CMS. Revisions may affect the code description, coverage, or rate — review each quarter's changes before submitting claims.
-
New Code 2023-Q2Inj, spesolimab-sbzo, 1 mg